The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma
Open accessAbstract
N6-methyladenosin (m6A) is one of the most pervasive modification of mRNA in eukaryotes and the m6A methyltransferases and demethylases play critical roles in many types of cancer. However the role of m6A-binding proteins in cancer remains elusive. Here we report that the down-regulation of YTHDF2 was specifically induced by hypoxia in hepatocellular carcinoma (HCC) cells, and that overexpression of YTHDF2 suppressed cell proliferation, tumor growth and activation of MEK and ERK in HCC cells. Mechanistically, YTHDF2 directly bound the m6A modification site of EGFR 3’-UTR to promote the degradation of EGFR mRNA in HCC cells. This is the first report showing that YTHDF2 may act as a tumor suppressor to repress cell proliferation and growth via destabilizing the EGFR mRNA in HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
N6-methyladenosine-dependent regulation of messenger RNA stability
Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q., Jia, G., et al. (2014) · Nature · doi:10.1038/nature12730 · Cited by 4,558
N6-methyladenosine Modulates Messenger RNA Translation Efficiency
Wang, X., Zhao, B. S., Roundtree, I. A., Lu, Z., Han, D., Ma, H., Weng, X., Chen, K., Shi, H., & He, C. (2015) · Cell · doi:10.1016/j.cell.2015.05.014 · Cited by 3,483
Self-citationTargeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Nuclear m6A Reader YTHDC1 Regulates mRNA Splicing
Xiao, W., Adhikari, S., Dahal, U., Chen, Y.-S., Hao, Y.-J., Sun, B.-F., Sun, H.-Y., Li, A., Ping, X.-L., Lai, W.-Y., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.01.012 · Cited by 2,054
Self-citationYTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA
Shi, H., Wang, X., Lu, Z., Zhao, B. S., Ma, H., Hsu, P. J., Liu, C., & He, C. (2017) · Cell Research · doi:10.1038/cr.2017.15 · Cited by 1,815
Self-citationThe m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells
Lin, S., Choe, J., Du, P., Triboulet, R., & Gregory, R. I. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.03.021 · Cited by 1,531
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA Demethylase
Li, Z., Weng, H., Su, R., Weng, X., Zuo, Z., Li, C., Huang, H., Nachtergaele, S., Dong, L., Hu, C., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.11.017 · Cited by 1,508
Du, H., Zhao, Y., He, J., Zhang, Y., Xi, H., Liu, M., Ma, J., & Wu, L. (2016) · Nature Communications · doi:10.1038/ncomms12626 · Cited by 1,463
Cited by
Functions of N6-methyladenosine and its role in cancer
He, L., Li, H., Wu, A., Peng, Y., Shu, G., & Yin, G. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1109-9 · Cited by 1,397
m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer
Huang, H., Weng, H., & Chen, J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.004 · Cited by 1,226
RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3
Niu, Y., Lin, Z., Wan, A., Chen, H., Liang, H., Sun, L., Wang, Y., Li, X., Xiong, X.-F., Wei, B., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1004-4 · Cited by 593
Self-citationThe role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities
Nombela, P., Miguel-López, B., & Blanco, S. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01263-w · Cited by 492
Zhang, C., Huang, S., Zhuang, H., Ruan, S., Zhou, Z., Huang, K., Ji, F., Ma, Z., Hou, B., & He, X. (2020) · Oncogene · doi:10.1038/s41388-020-1303-7 · Cited by 393
m6A modification: recent advances, anticancer targeted drug discovery and beyond
Deng, L.-J., Deng, W.-Q., Fan, S.-R., Chen, M.-F., Qi, M., Lyu, W.-Y., Qi, Q., Tiwari, A. K., Chen, J.-X., Zhang, D.-M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01510-2 · Cited by 366
The roles and implications of RNA m6A modification in cancer
Deng, X., Qing, Y., Horne, D., Huang, H., & Chen, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00774-x · Cited by 364
YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma
Hou, J., Zhang, H., Liu, J., Zhao, Z., Wang, J., Lu, Z., Hu, B., Zhou, J., Zhao, Z., Feng, M., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1082-3 · Cited by 361
m6A-binding proteins: the emerging crucial performers in epigenetics
Zhao, Y., Shi, Y., Shen, H., & Xie, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00872-8 · Cited by 316
Xu, J., Wan, Z., Tang, M., Lin, Z., Jiang, S., Ji, L., Gorshkov, K., Mao, Q., Xia, S., Cen, D., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01281-8 · Cited by 287
Mechanism of RNA modification N6-methyladenosine in human cancer
Zhou, Z., Lv, J., Yu, H., Han, J., Yang, X., Feng, D., Wu, Q., Yuan, B., Lu, Q., & Yang, H. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01216-3 · Cited by 275
Reading the m6A-encoded epitranscriptomic information in development and diseases
Chen, Y., Zhou, Z., Chen, Y., & Chen, D. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01293-7 · Cited by 24
Metadata
- Authors
- Zhong, L., Liao, D., Zhang, M., Zeng, C., Li, X., Zhang, R., Ma, H., & Kang, T.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 442
- Pages
- 252-261
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2899914600
- Cited by
- 372
- References
- 37
- FWCI
- 13.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.